-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, DK37tZr5G/QrieHUuvMCX19O42M5Qgh/btL3GWuwi0BAE1YIaX9ZMi48SAg3qTQG 5CSmT9DuA9T3wZSkxjHEcw== 0000908401-00-000002.txt : 20000216 0000908401-00-000002.hdr.sgml : 20000216 ACCESSION NUMBER: 0000908401-00-000002 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20000215 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: BIOMARIN PHARMACEUTICAL INC CENTRAL INDEX KEY: 0001048477 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 680397820 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: SEC FILE NUMBER: 005-56595 FILM NUMBER: 546013 BUSINESS ADDRESS: STREET 1: 11 PIMENTEL COURT CITY: NOVATO STATE: CA ZIP: 94949 MAIL ADDRESS: STREET 1: 11 PIMENTEL COURT STREET 2: 11 PIMENTEL COURT CITY: NOVATO STATE: CA ZIP: 94949 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: GLYKO BIOMEDICAL LTD CENTRAL INDEX KEY: 0000908401 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 680230537 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: ATTENTION: CONTROLLER STREET 2: 11 PIMENTEL COURT CITY: NOVATO STATE: CA ZIP: 94949 BUSINESS PHONE: 415-884-6725 MAIL ADDRESS: STREET 1: ATTENTION: CONTROLLER STREET 2: 11 PIMENTEL COURT CITY: NOVATO STATE: CA ZIP: 94949 SC 13G 1 SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* BioMarin Pharmaceutical Inc. (the "Issuer") (Name of Issuer) Common Stock (Title of Class of Securities) 09061G 10 1 (CUSIP Number) Check the following box if a fee is being paid with the statement ___. (A fee is not required only if the reporting person: (1) has a previous statement on file reporting beneficial ownership of more than five percent of the class of securities described in Item 1; and (2) has filed no amendment subsequent thereto reporting beneficial ownership of five percent or less of such class.) (See Rule 13d-7.). *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). SCHEDULE 13G ---------------------------------------- CUSIP No. 09061G 10 1 - ---------------------------------------- ------------------------------------ Page 2 of 5 Pages ------------------------------------ ------ ---------------------------------------------------------------------- 1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Glyko Biomedical Ltd. 98-0195569 ------ ---------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) (b) ------ ---------------------------------------------------------------------- 3 SEC USE ONLY ------ ---------------------------------------------------------------------- 4 CITIZENSHIP OR PLACE OF ORGANIZATION Canada ------ ---------------------------------------------------------------------- NUMBER OF 5 SOLE VOTING POWER SHARES 11,367,617 shares as of July 23, 1999 BENEFICIALLY (See Item 4(c) herein) OWNED BY EACH REPORTING PERSON WITH -------- -------------------------------------------------- 6 SHARED VOTING POWER 0 (See Item 4(c) herein) -------- -------------------------------------------------- 7 SOLE DISPOSITIVE POWER 11,367,617 shares as of July 23, 1999 (See Item 4(c) herein) -------- -------------------------------------------------- 8 SHARED DISPOSITIVE POWER 0 (See Item 4(c) herein) ----------------- -------- -------------------------------------------------- 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 11,367,617 shares of Common Stock (See Item 4(c)). ------- ----------------------------------------------------------------------- 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* ------- ----------------------------------------------------------------------- 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 32.6% ------- ----------------------------------------------------------------------- 12 TYPE OF REPORTING PERSON* Corporation ------- ----------------------------------------------------------------------- Item 1. (a) Name of the Issuer: BioMarin Pharmaceutical Inc. (the "Issuer") (b) Address of the Issuer: 371 Bel Marin Keys Blvd., Suite 210 Novato, CA 94949 Item 2. (a) Name of the Person Filing: Glyko Biomedical Ltd. (b) Address of the Principal Office: Scotia Plaza, Suite 2100 40 King Street West Toronto, Canada M5H 3C2 (c) Citizenship: Canada (d) Title of Class of Securities: BioMarin Pharmaceutical Inc. Common Stock ("Common Stock" or "Shares") (e) CUSIP Number: 09061G 10 1 Item 3. This statement is not being filed pursuant to Rule 13d-1(b) or 13d-2(b) Page 3 of 5 Item 4. Ownership a. Amount Beneficially Owned At July 23, 1999, the Reporting Person may be deemed to have beneficially owned an aggregate of 11,367,617 shares of Common Stock. All securities as being deemed owned by the Reporting person were purchased as follows: (a) 1,500,000 shares of Issuer's Common Stock ($0.001 Par Value)were acquired from the Issuer in a private placement on April 19, 1997 (b) 7,000,000 shares were issued by the Issuer as consideration for a License Agreement dated June 26, 1997 (c)166,667 shares were acquired from the Issuer in a private placement on June 30, 1998 (d) 2,259,039 shares issued by the Issuer as consideration for the Issuer's acquisition of Glyko, Inc. (formerly a wholly-owned subsidiary of the Reporting Person)(e) 441,911 shares were issued by the Issuer for the conversion of a convertible note plus accrued interest on July 23, 1999 and the shares were held and included in the above aggregate ownership. b. Percent of class At December 31, 1999, the Reporting person may be deemed to have beneficially owned approximately 32.6% of the outstanding shares of Common Stock. This percentage was calculated based upon 34,832,578 shares of Common Stock outstanding as of December 31, 1999. c. Power to vote or direct the vote and dispose or direct the disposition of securities At December 31, 1999, Reporting Person had the sole power to vote or direct the vote of, and the sole power to dispose or direct the disposition of, all 11,367,617 shares of Common Stock reported herein to be beneficially owned by the Reporting Person. The Reporting Person has no present intent to exercise its voting power in a manner which would change or influence the control of the Issuer. Page 4 of 5 Item 5. Ownership of Five percent or less of a Class Not Applicable Item 6. Ownership of Five percent or less of a Class Not Applicable Item 7. Identification and Classification of the Subsidiary which Acquired the Security being Reported on By the Parent Holding Company Not Applicable Item 8. Identification and Classification of Members of the Group Not Applicable Item 9. Notice of Dissolution of Group Not Applicable Item 10. Certification SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct. Date: February 15, 2000 /s/ Raymond W. Anderson ------------------------------------------ Raymond W. Anderson Director Page 5 of 5 -----END PRIVACY-ENHANCED MESSAGE-----